期刊文献+

帕病1号方对帕金森病模型大鼠的神经保护作用 被引量:5

Neuroprotection of Pabing Formula I for Rats with Parkinson's Disease
下载PDF
导出
摘要 目的探讨帕病1号方颗粒对帕金森病(PD)模型大鼠发挥神经保护作用的机制。方法采用6-羟基多巴胺纹状体两点注射法造成左侧纹状体损毁模型大鼠,把造模成功的40只大鼠分为3组:模型组(n=12),高剂量组(n=14),低剂量组(n=14)。另加正常组(n=8)。高、低剂量组每天分别给予帕病1号方颗粒18 g/kg,9 g/kg,模型组、正常组均予等体积蒸馏水。32 d后,行旋转测试;测定大鼠左侧纹状体匀浆中超氧化物歧化酶(SOD)活性及谷胱甘肽(GSH)、丙二醛(MDA)含量,免疫组化法检测中脑黑质P-Akt(ser 473)、Bcl-2、Bax表达。结果治疗后,与同期模型组相比,高、低剂量组旋转行为学明显改善(P<0.01),且存在量效关系(P<0.01)。与同期模型组相比,高剂量组SOD活性(P<0.01)和GSH含量明显提高(P<0.01),MDA含量降低(P<0.01);低剂量组GSH含量提高(P<0.01),MDA含量降低(P<0.01);与低剂量相比,高剂量组GSH含量提高(P<0.01),MDA含量降低了(P<0.01)。与模型组相比,高、低剂量组P-Akt(ser 473)、Bcl-2、Bax阳性细胞数及Bc1-2/Bax比值有显著性差异(P<0.05),且存在量效关系(P<0.05)。结论帕病1号方颗粒能提高大鼠抗氧化能力和清除自由基能力,同时激活Akt信号转导通路,发挥其神经保护作用。其神经保护作用呈一定的量效关系。 Objective To explore the neuroprotection of Pabing Formula I Granules for Parkinson's disease (PD) rats. Methods PD rats were induced with injection of 6-hydroxy dopamine twice stereotaxically into the left striatum. 40 rats modeled successfully were divided in-to model group (n=12), high dose group (n=14) and low dose group (n=14), and the other 8 rats were as normal group. The high dose group and low dose group received Pabing Formula I Granules 18 g/kg and 9 g/kg respectively, while the model group and normal group were giv-en distilled water at the same volume, once a day for 32 d. Then, they were assessed with rotation test. The activities of superoxide dis-mutase (SOD), the levels of glutathione (GSH) and malonaldehyde (MDA) of their left striatum were measured, and the expression of P-Akt (ser 473), Bcl-2, and Bax in substantia nigra were detected with immunohistochemistry. Results The rotation released was significant differ-ent among the model, high dose and the low dose groups after treatment (P〈0.01), with the activities of SOD (P〈0.01) and the content of GSH (P〈0.01) increasing and the content of MDA (P〈0.01) descreasing. There was significant difference in the content of GSH (P〈0.01) and MDA (P〈0.01) between the high and the low dose groups. There was significant difference in expression of P-Akt (ser 473), Bcl-2 and Bax among the model, high dose and the low dose groups, as well as the Bcl-2/Bad ratio (P〈0.05). Conclusion Pabing Formula I Granules plays neuroprotective effect through enhancing antioxidation and eliminating free radicals ability and Akt signaling pathway, which appears as dose-effect relationship.
出处 《中国康复理论与实践》 CSCD 北大核心 2013年第5期440-443,共4页 Chinese Journal of Rehabilitation Theory and Practice
基金 广东省科技计划项目(No.粤科规划字[2011]97-1)
关键词 帕金森病 帕病1号方 抗氧化作用 Akt信号转导通路 神经保护机制 Parkinson's Disease Pabing Formula I Granules antioxidation Akt signaling pathway neuroprotection
  • 相关文献

参考文献16

  • 1Toulouse A, Sullivan AM.. Progress in Parkinson's disease - where do we stand [J]. Prog Neurobiol, 2008, 85(4): 376-392.
  • 2刘国卿.神经元保护剂的研究进展[J].药学学报,2002,37(8):657-662. 被引量:46
  • 3Henchcliffe C, Severt WL. Disease modification in Parkinson's disease [J]. Drugs Aging, 2011, 28(8): 605-615.
  • 4PaxinosG,WatsonC.诸葛启钏,译.大鼠脑立体定位图谱[M].3版.北京:人民卫生出版社,2005:18.21.
  • 5Sinchez-Iglesias S, Rey P, M6ndez-Alvarez E, et al. Time-course of brain oxidative damage caused by intrastriatal administration of 6-hydroxydopamine in a rat model of Parkin- son's disease [J]. Neurochcm Res, 2007, 32(1): 99-105.
  • 6孙晓芳,王丹巧,吴兆恩,李鹏,牛建昭,王继峰,王巍.首乌方对帕金森病模型大鼠血液和纹状体细胞外液左旋多巴药代动力学影响的研究[J].中国实验方剂学杂志,2011,17(11):111-115. 被引量:14
  • 7Liu Q, Kou JP, Yu BY. Ginsenoside Rgl protects against hydro- gen peroxide-induced cell death in PC12 cells via inhibiting NF-nB activation [J]. Neurochem Int, 2011, 58(1): 119-125.
  • 8Duty S, Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the dis- ease [J]. Br J Pharmacol, 2011, 164(4): 1357-1391.
  • 9Iancu R, Mohapel P, Brundin P, et al. Behavioral characteriza- tion of a unilateral 6-OHDA-lesion model of Parkinson's dis- ease in mice [J]. Behav Brain Res, 2005, 162(1): 1-10.
  • 10何建成,王振华,袁灿兴,庄燕鸿.复方地黄方对帕金森病大鼠神经行为学及氧化应激的影响[J].中国康复医学杂志,2009,24(7):590-592. 被引量:27

二级参考文献74

共引文献101

同被引文献66

  • 1安利佳,李志刚,姜波.帕金森病与细胞凋亡[J].中国现代医学杂志,2006,16(7):1032-1036. 被引量:7
  • 2张振馨.帕金森病的诊断[J].中华神经科杂志,2006,39(6):408-409. 被引量:617
  • 3陈生弟.帕金森病治疗指南[J].中华神经科杂志,2006,39(6):409-412. 被引量:102
  • 4功能性胃肠病罗马Ⅲ诊断标准[J].胃肠病学,2006,11(12):761-765. 被引量:748
  • 5GEORGE PAXINOS.CHARLES WATSON.大鼠脑立体定位图谱[M].3版.北京:人民卫生出版社,2005:21.
  • 6Mattson MP. Neuronal life-and-death signaling, apoptosis, and neurode- generative disorders[J]. Antioxid Redox Signal, 2006,8 (11/12) : 1997-2006.
  • 7Zhao L, Vogt PK. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase pI3K):differential interactions with the regulatory subunit p85 and with RAS[J]. Cell Cycle, 2010,9 (3) : 596-600.
  • 8Maiese K, Chong ZZ, Wang S, et al. Oxidant stress and signal transduction in the nervous system with the PI 3-K,Akt,and mTOR cascade[J]. Int J Mol Sci,2012 , 13 (11) : 13830-13866.
  • 9Burke RE. Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways:Two approaches with therapeutic poten- tial in the treatment of neurodegenerative disease [J]. Pharmacol Ther, 2007,114(3) :261-277.
  • 10Zheng WH ,Kar S,Quirion R. Insulin-like growth factor-l-induced phos-phorylation of transcription factor FKHRL1 is mediated by phosphatidyli- nositol 3-kinase/Akt kinase and role of this pathway in insulin-like growth factor-l-induced survival of cultured hippocampal neurons[J]. Mol Phar- macol, 2002,62 ( 2 ) : 225 -233.

引证文献5

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部